Clinical Trials Directory

Trials / Sponsors / HRA Pharma

HRA Pharma

Industry · 14 registered clinical trials.

StatusTrialPhaseStarted
CompletedAdherence With Continuous-dose Oral Contraceptive: Evaluation of Self-Selection and Use
Contraception
Phase 32019-09-06
UnknownObservational Registry on Patients With Endogenous CS to Document Safety and Effectiveness of Ketoconazole.
Cushing Syndrome
—2018-12-20
CompletedEffect of Norgestrel 75 mcg on Cervical Mucus and Ovarian Activity During Perfect Use, After One Delayed Intak
Contraception
Phase 22018-07-24
TerminatedA Study of Oral Contraception Under Simulated OTC Conditions
Contraception
Phase 32018-04-27
CompletedA Study of Use of Ella®, an Emergency Contraceptive, Under Simulated OTC Conditions
Emergency Contraception
Phase 32017-05-23
CompletedEffects of Metyrapone in Patients With Endogenous Cushing's Syndrome
Cushing's Syndrome
Phase 32015-04-01
CompletedClinical Follow-up and Outcomes of Pregnancies Exposed to Ella
Emergency Contraception
—2014-11-18
CompletedAssessment of Effects on Ovarian Activity of a Combined Oral Contraceptive Pill When Preceded by the Intake of
Emergency Contraception
Phase 42012-03-01
CompletedSafety, Tolerability, and Efficacy of ellaOne® (Ulipristal Acetate) for Emergency Contraception in Postmenarch
Contraception
—2010-05-01
CompletedComparison of CDB-2914 Versus Placebo in the Prevention of Follicular Rupture Post-luteinizing Hormone (LH) Su
Contraception
Phase 22008-05-01
TerminatedProspective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing
Cushing's Syndrome
Phase 22007-05-15
CompletedSafety and Efficacy of CDB-2914 in Comparison to Levonorgestrel for Emergency Contraception
Contraception
Phase 32007-04-01
CompletedSafety and Efficacy of CDB-2914 for Emergency Contraception
Emergency Contraception
Phase 32006-11-01
CompletedLow Dose Continuous Administration of the Progesterone Receptor Modulator VA2914
Contraception, Gynecologic Diseases
Phase 22004-01-01